ACT Brief: DIA Leadership Amid Uncertainty, Reimagining CRO Contracts, and Eli Lilly Expansion

Applied Clinical Trials Online· June 25, 2026

Applied Clinical Trials has released a brief addressing significant shifts in the clinical research industry, including leadership changes at the Drug Information Association (DIA) and the reimagining of CRO contract structures. The report also highlights expansion efforts by Eli Lilly, reflecting a period of strategic growth and operational adjustment for major pharmaceutical players. These developments are particularly relevant for CROs and clinical trial sponsors navigating current market uncertainties and evolving partnership models.

Read the full story at Applied Clinical Trials Online

Summary generated by RabbitReport AI from public reporting. The full article and original reporting belong to Applied Clinical Trials Online.

More in Clinical Research & CRO

Samsung Partners With Alcedis to Advance Clinical Research Using Wearable-Based Endpoints

Samsung Electronics has entered a partnership with Alcedis, a digital-first clinical research organization, to transform wearable-captured biometrics into meaningful evidence for clinical trials. The collaboration seeks to address the industry-wide challenge of translating continuous, real-world health signals into clinically validated data for pharmaceutical and research organizations. By integrating advanced biosensors with clinical expertise, the two companies aim to maximize efficiency in terms of both cost and time during the research lifecycle.

June 29, 2026

Understanding and Preserving Data Flow Integrity in AI-Assisted Clinical Trials

Clinical trial sponsors must shift from viewing data integrity as a database-focused concern to an end-to-end information flow issue to manage the risks of AI integration. As AI tools are increasingly adopted by CROs and study partners for tasks like data cleaning and medical review, maintaining regulatory compliance requires strict adherence to ALCOA+ principles and robust oversight of outsourced activities. This approach is essential for meeting updated FDA and ICH expectations regarding trial reconstruction and sponsor accountability in an increasingly automated research environment.

June 26, 2026

Beyond Revenue Recognition: Rethinking CRO Contracting Through the CURED Shared Performance Contract

The clinical research industry is evaluating new contracting models, such as the CURED Shared Performance Contract, to evolve beyond traditional revenue recognition frameworks. This approach seeks to better align the financial and operational interests of sponsors and Contract Research Organizations (CROs) through shared performance metrics. Rethinking these agreements is critical for the sector as it aims to enhance trial efficiency and create more transparent partnership structures.

June 25, 2026

When Your CRO Gets Acquired Mid-Trial, the Site Pays the Operational Price

Tevogen Bio has announced plans to acquire a Contract Research Organization (CRO) and a Management Services Organization (MSO) as part of its post-SPAC growth strategy. This move highlights the significant operational disruptions clinical trial sites face during mid-study corporate integrations, including shifts in monitoring teams and documentation protocols. For the clinical research sector, these transitions necessitate heightened focus on regulatory compliance under 21 CFR Part 312.52 and ICH E6(R3) to ensure trial continuity and data integrity.

June 24, 2026